NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Forecast & News

Spectrum Pharmaceuticals' stock was trading at $2.39 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SPPI stock has decreased by 4.2% and is now trading at $2.29. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported ($0.35) EPS for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.02. The company's revenue was up NaN% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.30) earnings per share. View Spectrum Pharmaceuticals' earnings history.

4 Wall Street analysts have issued 1-year target prices for Spectrum Pharmaceuticals' shares. Their forecasts range from $4.00 to $19.00. On average, they expect Spectrum Pharmaceuticals' share price to reach $10.50 in the next year. This suggests a possible upside of 358.5% from the stock's current price. View analysts' price targets for Spectrum Pharmaceuticals.

Media coverage about SPPI stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term. View the latest news aboutSpectrum Pharmaceuticals.

Spectrum Pharmaceuticals saw a decline in short interest in March. As of March 13th, there was short interest totaling 6,300,300 shares, a decline of 8.8% from the February 27th total of 6,910,000 shares. Based on an average daily volume of 1,812,700 shares, the short-interest ratio is currently 3.5 days. Currently, 6.2% of the company's shares are sold short. View Spectrum Pharmaceuticals' Current Options Chain.

Some companies that are related to Spectrum Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Zynerba Pharmaceuticals (ZYNE), Progenics Pharmaceuticals (PGNX), Opko Health (OPK), TG Therapeutics (TGTX), Verastem (VSTM), Bausch Health Companies (BHC), AT&T (T) and Amicus Therapeutics (FOLD).

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Spectrum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (4.29%), Renaissance Technologies LLC (2.48%), Macquarie Group Ltd. (2.42%), Norges Bank (2.15%), Geode Capital Management LLC (1.36%) and FMR LLC (1.23%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View institutional ownership trends for Spectrum Pharmaceuticals.

SPPI stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, FMR LLC, Macquarie Group Ltd., Sargent Investment Group LLC, Sargent Investment Group LLC, Panagora Asset Management Inc., Citigroup Inc., and UBS Group AG. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Anthony E Maida III, Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner, Thomas J Riga, and William Ashton. View insider buying and selling activity for Spectrum Pharmaceuticals.

SPPI stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, State Street Corp, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Alpine Global Management LLC, Great West Life Assurance Co. Can, Nuveen Asset Management LLC, and Geode Capital Management LLC. View insider buying and selling activity for Spectrum Pharmaceuticals.

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SPPI stock can currently be purchased for approximately $2.29.

Spectrum Pharmaceuticals has a market capitalization of $262.89 million and generates $109.33 million in revenue each year. The biotechnology company earns $-112,690,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe. View additional information about Spectrum Pharmaceuticals.

The official website for Spectrum Pharmaceuticals is http://www.sppirx.com/.

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]